On November 5th, " Tainkang"Class 1.1 innovative drugsA press conference was held in Ma'anshan City, Anhui Province, to announce the publication of innovative research findings on CKBA for the treatment of Alzheimer's disease in the top international journal "Nature Aging". Taiencon announced the official launch of its preclinical research on CKBA for Alzheimer's disease.

　　"With the aging population, the number of Alzheimer's disease (AD) patients in China is continuing to grow, and there is an urgent need for a new theoretical system and drug solutions." When talking about the initial motivation for entering the Alzheimer's disease field, Zheng Hanjie, Chairman and General Manager of Taincon , said that CKBA has shown excellent potential in the AD field, and the company is full of confidence in developing CKBA products.

　　Accelerating the development of the Alzheimer's disease sector

　　Data shows that Alzheimer's disease, as the most common neurodegenerative disease in the world, has long faced "two major dilemmas": first, the core pathogenic mechanism is unclear; second, breakthroughs in traditional targets are limited, and a completely new theoretical system and drug solutions are urgently needed.

　　To address this critical issue, on October 29, the team led by Wang Honglin from the First Affiliated Hospital of Shanghai Jiao Tong University School of Medicine, the inventor of the innovative small molecule CKBA from the FIC brand, published a paper online in the top international journal "Nature Aging," demonstrating from a research perspective the development potential of CKBA as a new generation of small molecule candidate drugs from natural product sources that target immune metabolism.

　　This study reveals for the first time at the mechanistic level the key link of the "lipid-inflammation" axis, namely "lipid metabolism-microglia activation-neuroinflammation," in Alzheimer's disease, and clarifies the targeting value of MFE-2, a novel target of CKBA, as a cross-node, laying a theoretical foundation for the development of innovative drugs to intervene in Alzheimer's disease .

　　"Our team discovered in our research that oral administration of CKBA can treat Alzheimer's disease in mice by intervening in target sites. Now we have further modified the CKBA molecule to obtain a new compound with higher bioavailability," Wang Honglin explained. He added that the next step for this compound will be used in clinical research on anti-aging and Alzheimer's disease.

　　Wang Honglin stated that CKBA originates from traditional Chinese medicine.The innovative small molecule of class 1.1 derived from the active ingredient AKBA in frankincense achieved a triple effect of "improving cognitive function, reducing neuroinflammation, and reducing Aβ plaques" in AD model mice, breaking through the limitations of traditional drugs that are "difficult to penetrate the brain and have large side effects".

　　“We have seen a modernized path from traditional Chinese medicine to innovative drugs . The company plans to apply CKBA to clinical research on Alzheimer’s disease, tackling a major challenge in the treatment of Alzheimer’s disease,” said Zheng Hanjie.

　　At this press conference, the preclinical study of Taincon CKBA for the treatment of Alzheimer's disease was officially launched. Zheng Hanjie revealed that if the study proceeds smoothly, the company plans to advance to Phase I clinical trials in the second half of 2026.

　　CKBA offers broad prospects for new drug development.

　　Currently, China's innovative drug industry is booming, and drugs for cancer and autoimmune diseases have become popular areas for innovative drug companies to focus on in recent years.

　　"As an original small molecule drug, CKBA has shown excellent potential in immune-related diseases beyond Alzheimer's disease. CKBA will be the company's first step into the innovative drug track," said Zheng Hanjie.

　　Taking vitiligo as an example, "Vitiligo is a difficult-to-treat and easily relapsed chronic autoimmune skin disease, characterized by localized or generalized complete loss of skin pigmentation." Wang Honglin shared a set of data: The global incidence of vitiligo is about 1% to 3%, and among Chinese patients, 40% are children aged 2 to 12 years old, who have an urgent need for treatment.

　　Currently, Taincon is advancing a Phase III clinical trial of 1.5% CKBA for the treatment of vitiligo in children aged 2 to 12 years. CKBA is expected to become the world's first innovative drug for the treatment of childhood vitiligo.

　　"The company will fully advance the Phase III clinical trial of CKBA for vitiligo," said Zheng Hanjie. He added that, from a market perspective, the long-term market potential for innovative vitiligo drugs in China is expected to exceed 100 billion yuan.

　　CKBA's research and development progress in the treatment of rosacea is also quite encouraging. On the evening of September 25, Taienkang announced that its independently developed CKBA cream for the rosacea indication has been approved to conduct a Phase II/III seamless adaptive clinical trial. "We expect to officially start patient use by the end of this year and strive to obtain new drug approval for the rosacea indication in 2027," said Wang Honglin.

https://finance.eastmoney.com/a/202511063556217480.html